Nordisk wins label update for weight loss drug-device combo

Novo Nordisk (NYSE:NVO) said today that the FDA approved an updated label for its Saxenda liraglutide weight loss medicine. The therapy’s new label will include data showing that half of patients who received Saxenda and lost at least 5% of their weight after 56 weeks maintained their weight loss for 3 years.

The update is based on data from the company’s Scale obesity and pre-diabetes 3-year trial, which evaluated the long-term safety and efficacy of Saxenda in 3,731 adults.

Get the full story at our sister site, Drug Delivery Business News.

The post Nordisk wins label update for weight loss drug-device combo appeared first on MassDevice.

from MassDevice http://ift.tt/2oQqZza